PRIMARY STUDY
The endocannabinoid system and ophthalmic pathologies: a review of molecular mechanisms and its implications for clinical practice
Key Findings: This review covers the most up-to-date research concerning the endocannabinoid system and the major ophthalmic pathologies, including retinopathy and glaucoma. The existing literature shows promise in targeting the endocannabinoid system to alleviate disease.
Type of Study: Meta-analysis
Study Result: Positive
Research Location(s): Poland
Year of Pub: 2025
Cannabinoids Studied: Cannabidiol (CBD), Tetrahydrocannabinol (THC), AM-x Synthetic Cannabinoids, WIN-x Synthetic Cannabinoids, Anandamide (AEA), Fatty Acid Amide Hydrolase (FAAH), 2-Arachidonoyl Glycerol (2-AG), N-Arachidonoyl Dopamine (NADA), Palmitoylethanolamide (PEA), Omega-3, Omega-6
Phytocannabinoid Source: Not Applicable
Receptors Studied: CB1, CB2, GPCR 18, GPCR 55, PPAR - Alpha, PPAR - Gamma, PPARs, CB1 antagonist, CB2 agonist
Ligands Studied: Pro-inflammatory cytokines
Citation: Charytoniuk T, Półjanowski S, Michalak M, Kaźmierczak K, Kałużny B. The endocannabinoid system and ophthalmic pathologies: a review of molecular mechanisms and its implications for clinical practice. Front Med (Lausanne). 2025 Feb 5;12:1500179. doi: 10.3389/fmed.2025.1500179. PMID: 39975680; PMCID: PMC11835801.
